Goldwin

Goldwin Andrew is currently a Director Study Leader at AstraZeneca, bringing extensive experience in clinical trials across phases II - IV in various therapeutic areas. Previously, Andrew held the position of Global Study Manager at Roche from 2015 to 2018 and has served in multiple roles in clinical research at companies such as PAREXEL and Eisai. Andrew's educational background includes a BSc in Pharmaceutical Science from Sheffield Hallam University and ongoing studies at the University of the West of England.